Novel therapy for treating Multiple Sclerosis

治疗多发性硬化症的新疗法

基本信息

  • 批准号:
    7668842
  • 负责人:
  • 金额:
    $ 23.97万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-04-15 至 2011-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): A variety of therapies have been attempted to treat Multiple Sclerosis. Such experimental therapies have included the administration of myelin basic protein, administration of peptides derived from myelin basic protein, injection of the myelin basic protein peptide motif mimic, glatiramer acetate, and most recently, treating with DNA encoding myelin basic protein. The early clinical trials using such therapy have showed no, or little, clinical benefit. Based on these past clinical trials, it is clear that more efficacious therapies for Multiple Sclerosis patients are needed. The overall goal for the SBIR Phase I studies proposed here is to develop a novel formulation for use in treating Multiple Sclerosis patients. To begin to accomplish this task, we will express a novel protein in transgenic soybean seeds. The successful expression of this novel protein will allow soy formulations to be tested for efficacy in treating Multiple Sclerosis. To accomplish this task, the following milestones are proposed: Milestone #1: A novel fusion protein for treating Multiple Sclerosis will be expressed in transgenic soybeans. In milestone #1, we will establish soybean lines and produce soybean seeds in bulk quantities that can be used to make soy formulations for characterization (Milestone #2) and for use in efficacy studies (Milestone #3). Milestone #2: We will characterize the novel soybean-derived fusion protein and demonstrate that this protein retains it normal properties and functionality. Milestone #3: Demonstrate that soy formulations made from seeds expressing the fusion protein shows efficacy in treating a model of Multiple Sclerosis. Despite the disappointments and limited success of human clinical trials aimed at treating Multiple Sclerosis, the potential for such therapies is too great to ignore. In this Phase I SBIR, we propose to express a novel fusion protein in transgenic soybeans so that soy formulations can be assessed for their efficacy in treating a model of Multiple Sclerosis. Success with this Phase I SBIR studies will set the stage for future SBIR studies which will demonstrate safety and efficacy of such therapy in Multiple Sclerosis patients. PUBLIC HEALTH RELEVANCE: Based on past clinical trials, it is clear that more efficacious therapies for Multiple Sclerosis patients are needed. The overall goal for the SBIR Phase I studies proposed here is to develop a novel formulation for use in treating Multiple Sclerosis patients. The successful expression of this novel formulation will allow testing for efficacy in treating Multiple Sclerosis.
描述(由申请人提供):多种疗法已被尝试治疗多发性硬化症。这些实验性治疗包括髓磷脂碱性蛋白的治疗,髓磷脂碱性蛋白衍生的肽的治疗,注射髓磷脂碱性蛋白肽基序模拟物,醋酸格拉替默,以及最近用编码髓磷脂碱性蛋白的DNA治疗。使用这种疗法的早期临床试验显示没有或很少有临床效果。根据这些过去的临床试验,很明显,多发性硬化症患者需要更有效的治疗方法。这里提出的SBIR I期研究的总体目标是开发一种用于治疗多发性硬化症患者的新制剂。为了开始完成这项任务,我们将在转基因大豆种子中表达一种新的蛋白质。这种新蛋白的成功表达将使大豆配方在治疗多发性硬化症方面的功效得到测试。为了完成这项任务,我们提出了以下里程碑:里程碑#1:一种治疗多发性硬化症的新型融合蛋白将在转基因大豆中表达。在里程碑#1中,我们将建立大豆品系并批量生产大豆种子,这些大豆种子可用于制作大豆配方,用于鉴定(里程碑#2)和功效研究(里程碑#3)。里程碑2:我们将对新型大豆衍生融合蛋白进行表征,并证明该蛋白保留了其正常的特性和功能。里程碑3:证明由表达融合蛋白的种子制成的大豆配方对治疗多发性硬化症模型有效。尽管治疗多发性硬化症的人体临床试验令人失望且成功有限,但这种疗法的潜力太大了,不容忽视。在这个I期SBIR中,我们建议在转基因大豆中表达一种新的融合蛋白,以便大豆配方可以评估其治疗多发性硬化症模型的功效。这项I期SBIR研究的成功将为未来的SBIR研究奠定基础,这些研究将证明这种治疗在多发性硬化症患者中的安全性和有效性。公共卫生相关性:根据过去的临床试验,很明显需要对多发性硬化症患者进行更有效的治疗。这里提出的SBIR I期研究的总体目标是开发一种用于治疗多发性硬化症患者的新制剂。这种新配方的成功表达将允许测试治疗多发性硬化症的疗效。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KENNETH J PILLER其他文献

KENNETH J PILLER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KENNETH J PILLER', 18)}}的其他基金

Oral autoantigen therapy for the treatment of Multiple Sclerosis
口服自身抗原疗法治疗多发性硬化症
  • 批准号:
    10331867
  • 财政年份:
    2021
  • 资助金额:
    $ 23.97万
  • 项目类别:
Oral autoantigen therapy for the treatment of Multiple Sclerosis
口服自身抗原疗法治疗多发性硬化症
  • 批准号:
    10157209
  • 财政年份:
    2021
  • 资助金额:
    $ 23.97万
  • 项目类别:
Platform for practical delivery of oral autoantigens as co-therapies for neurological disease
口腔自身抗原作为神经系统疾病联合疗法的实际递送平台
  • 批准号:
    9341398
  • 财政年份:
    2016
  • 资助金额:
    $ 23.97万
  • 项目类别:
Improved diagnostic and monitoring assays for thyroid cancer
改进甲状腺癌的诊断和监测分析
  • 批准号:
    8591270
  • 财政年份:
    2010
  • 资助金额:
    $ 23.97万
  • 项目类别:
Improved diagnostic and monitoring assays for thyroid cancer
改进甲状腺癌的诊断和监测分析
  • 批准号:
    7907500
  • 财政年份:
    2010
  • 资助金额:
    $ 23.97万
  • 项目类别:
Improved diagnostic and monitoring assays for thyroid cancer
改进甲状腺癌的诊断和监测分析
  • 批准号:
    8885710
  • 财政年份:
    2010
  • 资助金额:
    $ 23.97万
  • 项目类别:
Improved diagnostic and monitoring assays for thyroid cancer
改进甲状腺癌的诊断和监测分析
  • 批准号:
    8692671
  • 财政年份:
    2010
  • 资助金额:
    $ 23.97万
  • 项目类别:
A Novel Therapy for Staphyloccocal Enterotoxin B poisoning
治疗葡萄球菌肠毒素 B 中毒的新疗法
  • 批准号:
    7271825
  • 财政年份:
    2007
  • 资助金额:
    $ 23.97万
  • 项目类别:
Efficacy of soybean-based vaccines using a model antigen
使用模型抗原的大豆疫苗的功效
  • 批准号:
    7256444
  • 财政年份:
    2005
  • 资助金额:
    $ 23.97万
  • 项目类别:
Efficacy of soybean-based vaccines using a model antigen
使用模型抗原的大豆疫苗的功效
  • 批准号:
    6926625
  • 财政年份:
    2005
  • 资助金额:
    $ 23.97万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 23.97万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 23.97万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 23.97万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 23.97万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 23.97万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 23.97万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 23.97万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 23.97万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 23.97万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 23.97万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了